All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Is venetoclax combined with low-dose chemo and HMA safe and efficacious in older patients with AML?

Dec 21, 2020

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Tapan Kadia, MD Anderson Cancer Center, Houston, US. We asked, Is venetoclax combined with low-dose chemo and hypomethylating agent (HMA) safe and efficacious in older patients with AML?

Is venetoclax combined with low-dose chemo and HMA safe and efficacious in older patients with AML?

Older and unfit patients with AML represent a difficult-to-treat population. In these patients, low-intensity therapy has been used for years because of the risk of toxicities and high rates of early mortality often observed with intensive chemotherapy. Unfortunately, although the low-intensity regimen is better tolerated, the response rates are modest. Recently, it has been shown that venetoclax, a BCL-2 inhibitor, in addition to HMAs improves response rates over HMAs alone. In this video, Kadia reports the promising results of a clinical trial evaluating the addition of venetoclax to the low-intensity backbone of cladribine plus low-dose cytarabine alternating with 5-azacytidine in older or unfit patients with newly diagnosed AML.